Edwards Lifesciences Corp. appears to be milking as many indications as possible from its transcatheter heart valve (THV) platform. The FDA just approved the company's Sapien XT valve for pulmonic valve replacement procedures in both adults and children with either a narrowed pulmonary valve or pulmonary regurgitation caused by congenital heart disease.